YOU STOPPED AT: “ LTERNATIVE APPROACHES (Less Common): ├─ Adjuvant radiation therapy (if high-risk features)" ├

COMPLETING YOUR ALTERNATIVE APPROACHES & TREATMENT DECISION FRAMEWORK

Let me finish the alternative approaches section and then provide you with a clear decision-making framework for your specific situation.

---

ALTERNATIVE APPROACHES (Less Common) - COMPLETE

ALTERNATIVE APPROACHES FOR YOUR SITUATION:

1. ADJUVANT RADIATION THERAPY (if high-risk features):
   ├─ Indication: Focal positive margin + Gleason 7
   ├─ Timing: Within 6-12 months of surgery
   ├─ Dose: 64-70 Gy over 6-8 weeks
   ├─ Benefit: Reduces 5-year BCR from 20-30% to 10-15%
   ├─ Trade-off: Radiation toxicity, overtreatment risk
   └─ Your case: Possible but NOT standard recommendation

2. ADJUVANT HORMONE THERAPY (if high-risk features):
   ├─ Indication: Gleason 7 + focal positive margin
   ├─ Duration: 6-24 months typically
   ├─ Benefit: Reduces recurrence risk by 5-15%
   ├─ Trade-off: Significant side effects, overtreatment risk
   └─ Your case: Possible but NOT standard recommendation

3. COMBINATION ADJUVANT THERAPY (Radiation + Hormone):
   ├─ Indication: High-risk features (you don't have all)
   ├─ Benefit: Maximum recurrence reduction
   ├─ Trade-off: Maximum toxicity and side effects
   ├─ Overtreatment risk: Very high for your situation
   └─ Your case: NOT recommended for pT2 disease

4. SALVAGE THERAPY (if recurrence occurs):
   ├─ Timing: Only if PSA rises above 0.2 ng/mL
   ├─ Options: Salvage radiation, hormone therapy, or both
   ├─ Benefit: Still highly effective if caught early
   ├─ Advantage: Avoids unnecessary treatment now
   └─ Your case: Most likely scenario if recurrence occurs

---

YOUR SPECIFIC TREATMENT DECISION - WHAT NCCN GUIDELINES SAY

Your Pathology Profile Summary

FAVORABLE FACTORS (Support Observation):
✓ pT2 stage - localized disease
✓ <5% cancer in each lobe - minimal disease burden
✓ No extraprostatic extension
✓ No seminal vesicle involvement
✓ No bladder neck involvement
✓ No lymphovascular invasion
✓ Negative margins at 3 of 4 locations
✓ Excellent PSA response (5.14 → 0.009 ng/mL)
✓ Undetectable PSA at 9.5 months

UNFAVORABLE FACTORS (Support Adjuvant Therapy):
✗ Gleason 7 (3+4) - intermediate grade
✗ 30% Gleason 4 component
✗ Perineural invasion present
✗ Focal positive margin at apex
✗ Pre-op PSA 5.14 ng/mL

NCCN RISK STRATIFICATION:
Your case = INTERMEDIATE-RISK PROSTATE CANCER
├─ Not low-risk (would have Gleason ≤6, negative margins)
├─ Not high-risk (would have Gleason 8-10, extensive margins)
└─ Intermediate = Requires careful surveillance

---

NCCN GUIDELINE RECOMMENDATION FOR YOUR CASE

According to NCCN Guidelines for Prostate Cancer (2024-2025)

PRIMARY RECOMMENDATION:
┌──────────────────────────────────────────────────────────┐
│ OBSERVATION WITH PSA SURVEILLANCE                        │
│                                                          │
│ Rationale for your specific situation:                   │
│ • pT2 stage (best-case surgical stage)                   │
│ • Focal positive margin (not extensive)                  │
│ • No seminal vesicle invasion                            │
│ • No extraprostatic extension                            │
│ • Gleason 7 (intermediate, not high-grade)               │
│ • Excellent PSA response to surgery                      │
│ • 70-80% will remain cancer-free at 5 years              │
│ • Salvage therapy highly effective if needed             │
│ • Avoids overtreatment of 70-80% who won't recur         │
└──────────────────────────────────────────────────────────┘

ALTERNATIVE CONSIDERATION:
Adjuvant radiation therapy MAY be considered if:
├─ Patient preference for maximum recurrence reduction
├─ Ability to tolerate radiation toxicity
├─ Concern about future salvage therapy
└─ Shared decision-making with oncologist

NOT RECOMMENDED:
✗ Adjuvant hormone therapy alone (insufficient indication)
✗ Combination adjuvant therapy (overtreatment for pT2)

---

YOUR SURVEILLANCE PLAN - DETAILED TIMELINE

What You Should Expect Over the Next 5 Years

Based on NCCN Guidelines for Post-Prostatectomy Surveillance:

PHASE 1: MONTHS 0-12 (You are currently here at 9.5 months)

Current status:
├─ Surgery date: ~[date removed]
├─ Current date: ~[date removed]
├─ Time elapsed: 9.5 months
├─ Current PSA: 0.009 ng/mL (undetectable)
└─ Status: Excellent response

Remaining tests in Phase 1:
├─ [date removed] (3 months from last test)
│  └─ Expected result: 0.005-0.015 ng/mL
├─ [date removed] (6 months from last test)
│  └─ Expected result: 0.005-0.015 ng/mL
└─ [date removed] (9 months from last test)
   └─ Expected result: 0.005-0.015 ng/mL

Phase 1 goal:
├─ Confirm PSA remains undetectable
├─ Establish baseline pattern
├─ Rule out early recurrence
└─ Provide reassurance

PHASE 2: MONTHS 12-24 (Year 2 post-op)

Timeline:
├─ [date removed]: 12 months post-op
│  └─ PSA expected: 0.005-0.015 ng/mL
├─ [date removed]: 15 months post-op
│  └─ PSA expected: 0.005-0.015 ng/mL
├─ [date removed]: 18 months post-op
│  └─ PSA expected: 0.005-0.015 ng/mL
└─ [date removed]: 24 months post-op
   └─ PSA expected: 0.005-0.015 ng/mL

Testing frequency:
├─ Can transition to every 3-6 months
├─ Depends on continued undetectable PSA
└─ Physician may extend intervals

Phase 2 goal:
├─ Confirm sustained undetectable PSA
├─ Assess for late recurrence signals
├─ Transition to less frequent monitoring
└─ Provide continued reassurance

PHASE 3: MONTHS 24-60 (Years 3-5 post-op)

Timeline:
├─ Year 3 (May 2028): PSA every 6 months
├─ Year 4 (May 2029): PSA every 6-12 months
├─ Year 5 (May 2030): PSA every 6-12 months
└─ Beyond Year 5: PSA every 12 months indefinitely

Testing frequency:
├─ Can extend to every 6-12 months
├─